Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

Company Overview - Mapi Pharma Ltd. is a late-stage clinical development biopharmaceutical company focused on innovative long-acting depot injectable treatments [1] - The company is developing Glatiramer Acetate Depot (GA Depot), a once-monthly injection for multiple sclerosis, currently in clinical studies for relapsing forms of MS and undergoing final review in Germany [3][10] Upcoming Event - Mapi Pharma will host a virtual key opinion leader (KOL) event on March 3, 2026, featuring discussions on unmet needs in multiple sclerosis treatment and Mapi's depot technology [1][2] - Presenters include Dr. Aaron Miller and Dr. Carlo S. Tornatore, who will address the treatment landscape for Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Forms of Multiple Sclerosis (RMS) [2] Clinical Trial Results - The Phase IIa clinical trial of GA Depot for PPMS involved 30 patients, showing stable overall disability with mean EDSS scores improving from 5.1 to 4.5 over three years [7] - A disability progression-free rate of 96.6% was observed, with 89.7% of patients maintaining stable physical function on the 9-Hole Peg Test [8] - Treatment was well tolerated, with 81.6% of adverse events being mild, primarily injection site reactions [9] Product Pipeline and Market Strategy - Mapi Pharma is advancing its product pipeline, including GA Depot for RMS and PPMS, and is also developing depot long-acting injections for other medical indications [10] - The company has partnered with Viatris for the commercialization of GA Depot and is engaged in developing generic versions of other medications in specific markets [10]